The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지
DOI QR코드

DOI QR Code

Gamitaeeumjowee-Tang for weight loss in diabetic patients: A retrospective chart review

당뇨 환자의 체중감량을 위한 가미태음조위탕의 임상적 활용: 후향적 차트 리뷰

  • Received : 2021.01.29
  • Accepted : 2021.02.18
  • Published : 2021.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The purpose of this study is to report weight changes and analyze adverse events in diabetic patients with Gamitaeeumjowee-Tang for weight loss. Methods: A retrospective chart review of weight change and adverse events was performed during the 10-week weight loss program using Gamitaeeumjowee-tang with low-calorie diets for diabetics(n=61). Weight and BMI changes were compared before and after the program and calculated the percentage of people who lost more than 5% of their weight, also identified whether subjects felt satiated or not. Adverse events were evaluated in terms of causality, severity and system-organ classes. Results: After 10-week weight loss program, significant weight loss (5.9±2.32kg, 7.73% reduction from baseline) and BMI reduction (2.9±0.86) were reported (n=61). Those who lost more than 5 percent of their body weight accounted for 88.5%, and also 88.5% of the participants felt full to help control their appetite. In assessing the causality of adverse events, 'Unlikely' was the most common (66%) and in severity evaluations, almost all symptoms were mild. Insomnia was the most frequently reported during the first 8 weeks, and constipation was reported the most afterwards. Conclusions: A combination of Gamitaeeumjowee-tang and low-calorie diets for 10 weeks appears to help weight reduction without serious adverse events in diabetic patients. Future well-designed prospective clinical studies testing the effectiveness and safety of this weight loss program are warranted.

Keywords

References

  1. Korean Diabetes Association. Treatment Guideline for Diabetes. 2018;13,17.
  2. Jang HC, Choi SH. Characterization of Patients with Type 2 Diabetes according to Body Mass Index: Korea National Health and Nutrition Examination Survey from 2007 to 2011. Endocrinol Metab. 2015;30:514-21. https://doi.org/10.3803/EnM.2015.30.4.514
  3. Korean Obesity Association. Treatment Guideline for Obesity.2018;17-18.
  4. Korean Diabetes Association. Diabetes Fact Sheet. 2018.
  5. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61. https://doi.org/10.2337/diacare.27.1.155
  6. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34:1481-6. https://doi.org/10.2337/dc10-2415
  7. Kim DH, Park SC, Lee JH, Lee HY, Cho MK, Cho JYi, et al. Recent Research Trends in Korean Medicine Treatment of Diabetes Mellitus - Focusing on Domestic Articles from 2008 to 2013 -. Korean J Orient Int Med. 2013;4(3):240-55.
  8. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, et al. Diabetes Intervention Study, Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care. 1991;14: 308-17. https://doi.org/10.2337/diacare.14.4.308
  9. United Kingdom Prospective Diabetes Study (UK-PDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83-8. https://doi.org/10.1136/bmj.310.6972.83
  10. Lee MJ, Kim SS. Management of Obesity in Patients with Diabetes Mellitus. J Korean Diabetes, 2017;18:229-38, https://doi.org/10.4093/jkd.2017.18.4.229
  11. Chon S, Park CY, Koh GP, Oh SJ, Woo JT, Kim SW et al. The Effect of Orlistat in Obese Patients with Type 2 Diabetes : Benefit on Abdominal Obesity and Glycemic Control. J Korean Med Obes Res. 2004;13(4):281-92.
  12. Lee EJ, Kim TN. Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. Korean J Obes. 2016;25(3):121-8. https://doi.org/10.7570/kjo.2016.25.3.121
  13. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426-36. https://doi.org/10.1038/oby.2012.66
  14. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022-9. https://doi.org/10.2337/dc13-0234
  15. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA. 2015;314:687-99. https://doi.org/10.1001/jama.2015.9676
  16. Han HJ, Kim HJ, Park EY, Jang JA, An TH, Seo HS , et al. The effect of oriental obesity therapy on Morbid obese patient with Type 2 Diabetes : Two Cases Report. J Korean Med. 2010;10:57-63.
  17. Kim HJ, Kim KS. Improvement of type 2 diabetes by very-low-calorie diet-A case report. J Korean Med. 2002;2(1):97-102.
  18. Cha YY. A case Study on the Treatment of Obese patient with diabetes. J Korean Med. 2004;4(1):193-9.
  19. World Health Organization-Uppsala Monitoring Centre (WHO-UMC). Causality categories [Internet]. Uppsala (Sweden): World Health Organization-Uppsala Monitoring Centre (WHO-UMC); 2018. [cited 2012 Oct 22]. Available from: https://who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf.
  20. Korea Institute of Drug Safety & Risk Management. Adverse Drug Reaction Assessment Report. 1st ed. Seoul : Korea Institute of Drug Safety & Risk Management. 2013:60-3.
  21. National Cancer Institute. National Institute of Health. U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2010.
  22. Basch E, Reeve B, Mitchell S, Clauser S, Minasian L, Dueck A, et al. Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 2014;106(9):244.
  23. Korea Institute of Drug Safety & Risk Management. Terminology Guide for Reporting Adverse Drug Reactions. Seoul : Korea Institute of Drug Safety & Risk Management. 2014:1-6.
  24. Lee JM. Longevity and life preservation in Eastern medicine, Seoul : Haklimsa. 1986;333-8.
  25. Lee JE, Song YK, Lim HH. Clinical trial of Taeeumjowui-tang (Taiyintiaowei-tang) on obese patients: randomized, double blind, placebo-controlled study. J Orient Rehab Med. 2010;20(4):197-213.
  26. Lim SY, Park SW, Joo JH, Kim SR, Kim DJ, Choi WS. The effects of Taeeumjowui-tang (Taiyintiaowei-tang) on obesity in Sasang constitution. J East-West Med. 2012;37(4):109-16.
  27. Park SJ, Nahmkoong W, Cheon CH, Park JS, Jang BH, Shin YC, et al. Efficacy and safety of Taeeumjowi-tang in obese Korean adults: a double-blind, randomized, and placebo-controlled pilot trial. Evid-Based Complement Altern Med. 2013;2013:498935.
  28. Hwang MJ, Shin HD, Song MY. Literature review of herbal medicines on treatment of obesity since 2000; mainly about Ephedra Herba. J Korean Med Obes Res. 2007;7(1):39-54.
  29. Jang IS, Hwang EH. The Need for Clinical Practice Guidelines in Usage of Mahuang in Weight Loss. J Korean Med Obes Res. 2007;(1):23-9.
  30. Jo GW, OK JM, Kim SY, Lim YW. Review on the efficacy and safety of Mahuang and ephedrine in the treatment of obesity-focused on RCT. J Korean Med. 2017;38(3):170-84. https://doi.org/10.13048/jkm.17034
  31. Wing RR, Marcus MD, Epstein LH, Jawad A. A "family-based" approach to the treatment of of obese Type II diabetic patients. J Consult Clin Psychol. 1991;59:156-62. https://doi.org/10.1037/0022-006X.59.1.156
  32. Yoon NR, Yoo YJ, Kim MJ, Kim SY, Lim YW, Lim HH et al. Analysis of Adverse Events in Weight Loss Program in Combination with 'Gamitaeeumjowee-Tang' and Low-Calorie Diet. J Korean Med Obes Res. 2018;18(1):1-9. https://doi.org/10.15429/jkomor.2018.18.1.1
  33. Kim HJ, Kim JY. Clinical report about the adverse reactions of Taeeumin.Soeumin.Soyangin by Taeeumjowi-tang. Korean J Oriental Physiology & Pathology. 2008;22(6):1600-5.
  34. Luyster FS, Dunbar-Jacob J. Sleep quality and quality of life in adults with type 2 diabetes. Diabetes Educ. 2011;379:347-55. https://doi.org/10.1177/0145721711400663
  35. Jain A, Sharmab R, Yadavc N, Chaudhary P, Jainc G, Maanju M. Quality of life and its association with insomnia and clinical variables in type 2 diabetes. J Egypt Public Health Assoc. 2017;92(1):52-9. https://doi.org/10.21608/epx.2018.6651
  36. Attarian H, Hachul H, Guttuso T, Phillips B. Treatment of chronic insomnia disorder in menopause: Evaluation of literature. Menopause. 2015;22(6):674-84. https://doi.org/10.1097/GME.0000000000000348
  37. Hwa Kim. Diagnosis and Management of Diabetic Autonomic Neuropathy Chong. J Korean Diabetes. 2018;19:160-7. https://doi.org/10.4093/jkd.2018.19.3.160
  38. Christensen P, Bliddal H, Riecke BF, Leeds AR, Astrup A, Christensen R. Comparison of a low-energy diet and a very low-energy diet in sedentary obese individuals: a pragmatic randomized controlled trial. Clin Obes. 2011;1(1):31-4. https://doi.org/10.1111/j.1758-8111.2011.00006.x
  39. Kim JS, Yoon SH. Effect of Naesosan gastric motility between normal intact and antral dilatated rats. J Korean Orient Int Med. 2008;29(1):117-129.